This inventor holds 3 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignees: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts, Eberhard-Karls-Universitat Tubingen. Active years: 2023-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 168 
3 out of 16 Years Active: 2023-2025
Title: Gundram Jung: Innovator in Antibody Research
Introduction
Gundram Jung is a notable inventor based in Rottenburg, Germany. He has made significant contributions to the field of antibody research, holding a total of 3 patents. His work focuses on developing novel antibodies with potential applications in diagnostics and therapeutics.
Latest Patents
One of his latest patents is titled "PSMA binding antibody and uses thereof." This invention introduces a novel PSMA binding antibody known as 10B3, which has pharmaceutical and diagnostic applications. The antibody 10B3 does not cross-compete with the established PSMA binding antibody J591 and exhibits a reduced induction of antigen shift compared to J591. Additionally, it shows unique reactivity with squamous cell carcinoma (SCC) cells of various origins.
Another significant patent is for "Anti-FLT antigen binding proteins." This invention provides novel human fins related to tyrosine kinase 3 (FLT) antigen binding proteins, including antibodies that demonstrate improved FLT binding affinity and anti-tumor activity. The FLT antibodies were generated through mutation of a parent FLT antibody and were tested in vitro in binding assays, as well as in vivo in mouse tumor models and human patient tumor samples. These antibodies can be provided as monospecific constructs or in a bispecific FLT×CD antibody format, showcasing excellent target affinity and tumor cell killing capabilities. The invention also includes methods for producing these antigen binding proteins, along with nucleic acids encoding them, vectors for their expression, and host cells. Furthermore, it relates to methods for treating or diagnosing diseases such as leukemia using an FLT antigen binding protein.
Career Highlights
Gundram Jung has worked with prestigious institutions, including the German Cancer Research Center (Deutsches Krebsforschungszentrum) and Eberhard Karls University of Tübingen. His research has significantly advanced the understanding and application of antibody technology in cancer treatment.
Collaborations
He has collaborated with notable colleagues, including Helmut Salih and Fabian Vogt, contributing to the advancement of innovative research in the field.
Conclusion
Gundram Jung's contributions to antibody research have the potential to impact diagnostics and therapeutics significantly. His innovative patents reflect his dedication to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile